Mechanism of Action
PTH1R Activation
PTHrP(1-34) and PTH share the same N-terminal binding sequence for PTH1R. PTH1R is a class B GPCR that couples to Gs and Gq, increasing cAMP and intracellular calcium. In bone, PTH1R activation on osteoblasts stimulates RANKL expression, driving osteoclastogenesis and bone resorption. In kidney, PTH1R stimulates 1-alpha-hydroxylase activity, increasing active vitamin D (calcitriol) production.
Paracrine vs. Endocrine Actions
Unlike PTH (an endocrine hormone), PTHrP normally acts in a paracrine and autocrine manner in tissues including growth plates, mammary glands, placenta, and smooth muscle. Pathologically, tumor-derived PTHrP is released into the circulation, causing systemic hypercalcemia. The mid-region and C-terminal domains of PTHrP have separate biological activities not shared with PTH.
Research Summary
Humoral Hypercalcemia of Malignancy
ClinicalPTHrP secretion accounts for approximately 80% of humoral hypercalcemia of malignancy (HHM). Anti-PTHrP antibodies and PTH1R antagonists are therapeutic strategies being evaluated. Serum PTHrP is a diagnostic marker for HHM and correlates with tumor burden and hypercalcemia severity in breast, lung, and renal cell cancers.
Anabolic Bone Effects
FDA Approved (related)Abaloparatide, a synthetic PTHrP analog optimized for bone anabolic signaling, is FDA-approved for osteoporosis. Intermittent PTH1R activation through abaloparatide or teriparatide (PTH 1-34) promotes bone formation. This anabolic effect contrasts with the catabolic bone effects of continuously elevated PTHrP in cancer.
Calculate your PTHrP dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Bone metabolism research | 1-100 nM PTHrP(1-34) | Variable | Cell culture / in vivo |
| HHM diagnostic assay | Serum PTHrP measurement | Clinical diagnostic | Immunoassay |
PTHrP itself is not therapeutically administered; abaloparatide and teriparatide are the clinical PTH1R agonists.
Interactions
Safety Profile
PTHrP is an endogenous protein with critical developmental roles. Pathological PTHrP overexpression in cancer causes hypercalcemia, which is life-threatening if untreated. Anti-PTHrP therapeutic antibodies are in development; no approved anti-PTHrP therapy exists as of 2025. Related PTH1R agonists (abaloparatide, teriparatide) carry a boxed warning for osteosarcoma risk with prolonged use.
References
- [1]Wysolmerski JJ (2012). Parathyroid hormone-related protein: an update. Journal of Clinical Endocrinology and Metabolism, 97(9), 2947-2956.
- [2]Burtis WJ et al. (1987). Identification of a novel 17,000-dalton parathyroid hormone-like adenylate cyclase-stimulating protein from a tumor associated with humoral hypercalcemia of malignancy. Journal of Biological Chemistry, 262(15), 7151-7156.